Advanced Genetic Technologies

American Gene Technologies (AGT) is a clinical-stage gene therapy company based in Rockville, Maryland, specializing in the development of lentiviral-based treatments for infectious diseases, cancers, and inherited disorders. The company is best known for its lead candidate, AGT103-T, an autologous cell therapy designed to provide a functional cure for HIV by repairing the immune system's ability to control the virus. In 2023, AGT launched Addimmune, a dedicated entity focused on advancing the HIV program through late-stage clinical trials and commercialization. Beyond HIV, AGT’s pipeline includes promising gene therapy candidates for Phenylketonuria (PKU) and solid tumors like liver cancer. The company leverages a sophisticated drug-delivery platform to create precision genetic medicines aimed at transforming the treatment landscape for chronic and life-threatening conditions.